Neuronetics Inc - Understand $stim stock

$STIM Market Cap: $18.5 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$72.71M

TTM

Gross Margin

75.6%

TTM

Net Earnings

-$36.42M

TTM

Current Assets

$53.46M

Q3 2024

Current Liabilities

$16.90M

Q3 2024

Current Ratio

316.38%

Q3 2024

Total Assets

$74.12M

Q3 2024

Total Liabilities

$64.74M

Q3 2024

Book Value

$9.381M

Q3 2024

Cash

$20.90M

Q3 2024

P/E

-0.5079

Nov 13, 2024 EST

Free Cash Flow

-$16.71M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$71.35M	$65.21M	$55.31M	$49.24M	$62.66M	$52.78M	$40.43M	$34.23M
YoY Change	9.42%	17.89%	12.32%	-21.41%	18.72%	30.53%	18.13%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$71.35M	$65.21M	$55.31M	$49.24M	$62.66M	$52.78M	$40.43M	$34.23M
Cost Of Revenue	$19.64M	$15.48M	$11.65M	$11.55M	$15.39M	$12.45M	$9.632M	$6.622M
Gross Profit	$51.71M	$49.72M	$43.66M	$37.69M	$47.27M	$40.33M	$30.80M	$27.61M
Gross Profit Margin	72.47%	76.26%	78.93%	76.54%	75.44%	76.42%	76.18%	80.65%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$72.74M	$75.50M	$63.30M	$50.80M	$60.45M	$51.93M	$36.47M	$28.72M
YoY Change	-3.65%	19.27%	24.61%	-15.97%	16.41%	42.38%	26.99%
% of Gross Profit	140.69%	151.84%	144.99%	134.78%	127.89%	128.77%	118.41%	104.04%
Research & Development	$9.515M	$9.336M	$7.923M	$9.201M	$13.75M	$8.230M	$7.940M	$8.220M
YoY Change	1.92%	17.83%	-13.89%	-33.07%	67.04%	3.65%	-3.41%
% of Gross Profit	18.4%	18.78%	18.15%	24.41%	29.08%	20.41%	25.78%	29.78%
Depreciation & Amortization	$2.006M	$1.648M	$1.060M	$941.0K	$1.065M	$882.0K	$596.0K	$673.0K
YoY Change	21.72%	55.47%	12.65%	-11.64%	20.75%	47.99%	-11.44%
% of Gross Profit	3.88%	3.31%	2.43%	2.5%	2.25%	2.19%	1.94%	2.44%
Operating Expenses	$82.26M	$84.83M	$71.22M	$60.00M	$74.20M	$60.16M	$36.47M	$36.95M
YoY Change	-3.04%	19.11%	18.71%	-19.14%	23.33%	64.96%	-1.29%
Operating Profit	-$30.55M	-$35.11M	-$27.56M	-$22.31M	-$26.93M	-$19.83M	-$13.61M	-$9.344M
YoY Change	-12.98%	27.38%	23.56%	-17.16%	35.78%	45.75%	45.63%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$5.424M	$4.251M	$4.019M	$4.522M	$3.685M	$3.688M	$2.808M	$1.835M
YoY Change	27.59%	5.77%	-11.12%	22.71%	-0.08%	31.34%	53.02%
% of Operating Profit
Other Income/Expense, Net	$5.789M	$2.203M	$390.0K	$302.0K	$1.571M	-$575.0K	$357.0K	-$62.00K
YoY Change	162.78%	464.87%	29.14%	-80.78%	-373.22%	-261.06%	-675.81%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	-$30.19M	-$37.16M	-$31.19M	-$27.45M	-$29.00M	-$24.10M	-$16.10M	-$11.20M
YoY Change	-18.76%	19.13%	13.64%	-5.34%	20.33%	49.69%	43.75%
Income Tax
% Of Pretax Income
Net Earnings	-$30.20M	-$37.20M	-$31.20M	-$27.50M	-$29.00M	-$24.10M	-$16.06M	-$11.23M
YoY Change	-18.82%	19.23%	13.45%	-5.17%	20.33%	50.07%	42.95%
Net Earnings / Revenue	-42.33%	-57.05%	-56.41%	-55.84%	-46.28%	-45.66%	-39.72%	-32.82%
Basic Earnings Per Share	-$1.05	-$1.38	-$1.22	-$1.46	-$1.58
Diluted Earnings Per Share	-$1.05	-$1.38	-$1.22	-$1.46	-$1.58	-$2.693M	-$988.3K	-$691.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$59.68M	$70.34M	$94.14M	$49.00M	$75.70M	$104.6M	$29.10M	$17.00M
YoY Change	-15.16%	-25.28%	92.12%	-35.27%	-27.63%	259.45%	71.18%
Cash & Equivalents	$59.68M	$70.34M	$94.14M	$49.00M	$75.70M	$104.6M	$29.10M	$17.00M
Short-Term Investments
Other Short-Term Assets	$7.280M	$4.171M	$4.649M	$3.300M	$2.500M	$1.800M	$1.100M	$600.0K
YoY Change	74.54%	-10.28%	40.88%	32.0%	38.89%	63.64%	83.33%
Inventory	$8.093M	$8.899M	$6.563M	$3.700M	$2.800M	$2.400M	$2.500M	$1.700M
Prepaid Expenses
Receivables	$15.78M	$13.59M	$7.706M	$7.200M	$6.600M	$5.600M	$4.300M	$3.600M
Other Receivables	$2.961M	$1.768M	$2.272M	$1.900M	$800.0K	$0.00	$0.00	$0.00
Total Short-Term Assets	$93.79M	$98.77M	$115.3M	$65.00M	$88.50M	$114.5M	$37.00M	$22.90M
YoY Change	-5.04%	-14.36%	77.43%	-26.55%	-22.71%	209.46%	61.57%
Property, Plant & Equipment	$4.782M	$5.318M	$5.104M	$5.300M	$4.900M	$1.400M	$1.400M	$1.600M
YoY Change	-10.08%	4.19%	-3.7%	8.16%	250.0%	0.0%	-12.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.80M	$11.21M	$8.981M	$6.000M	$5.100M	$1.200M	$600.0K	$300.0K
YoY Change	14.15%	24.85%	49.68%	17.65%	325.0%	100.0%	100.0%
Total Long-Term Assets	$22.04M	$18.12M	$25.89M	$13.70M	$11.70M	$2.500M	$1.900M	$1.900M
YoY Change	21.66%	-30.04%	88.99%	17.09%	368.0%	31.58%	0.0%
Total Assets	$115.8M	$116.9M	$141.2M	$78.70M	$100.2M	$117.0M	$38.90M	$24.80M
YoY Change
Accounts Payable	$4.752M	$2.433M	$4.299M	$3.700M	$4.600M	$3.800M	$2.500M	$1.500M
YoY Change	95.31%	-43.41%	16.19%	-19.57%	21.05%	52.0%	66.67%
Accrued Expenses	$12.39M	$14.86M	$7.923M	$7.300M	$9.000M	$7.100M	$7.500M	$6.000M
YoY Change	-16.65%	87.57%	8.53%	-18.89%	26.76%	-5.33%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$13.13M	$0.00	$0.00	$11.30M		$0.00	$4.500M
YoY Change				-100.0%			-100.0%
Total Short-Term Liabilities	$19.81M	$33.20M	$15.70M	$13.70M	$27.70M	$13.60M	$12.00M	$13.30M
YoY Change	-40.32%	111.42%	14.62%	-50.54%	103.68%	13.33%	-9.77%
Long-Term Debt	$59.28M	$22.83M	$35.34M	$34.60M	$19.90M	$30.40M	$30.00M	$16.10M
YoY Change	159.68%	-35.39%	2.12%	73.87%	-34.54%	1.33%	86.34%
Other Long-Term Liabilities	$2.546M	$3.796M	$5.010M	$4.900M	$4.700M	$2.000M	$2.400M	$200.0K
YoY Change	-32.93%	-24.23%	2.24%	4.26%	135.0%	-16.67%	1100.0%
Total Long-Term Liabilities	$61.83M	$26.63M	$40.35M	$39.50M	$24.60M	$32.40M	$32.40M	$16.30M
YoY Change	132.22%	-34.01%	2.14%	60.57%	-24.07%	0.0%	98.77%
Total Liabilities	$81.64M	$59.82M	$56.05M	$53.20M	$52.30M	$46.00M	$44.50M	$29.60M
YoY Change	36.47%	6.74%	5.35%	1.72%	13.7%	3.37%	50.34%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	28.66M	26.90M	25.48M	18.84M	18.38M
Diluted Shares Outstanding	28.66M	26.90M	25.48M	18.84M	18.38M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $18.5 Million

About Neuronetics Inc

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 202 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Pulse Biosciences Inc Electromed Inc enVVeno Medical Corp LENSAR Inc Lucid Diagnostics Inc Neuropace Inc PAVmed Inc Pro-Dex Inc